Qingdao Baheal Medical INC. (SHE:301015)
China · Delayed Price · Currency is CNY 25.86
-0.34 (-1.30%)
Aug 21, 2026, 3:04 PM CST
SHE:301015 Ratios and Metrics
Market cap in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
| 13,593 | 12,405 | 12,725 | 18,830 | 12,518 | 15,911 | |
Market Cap Growth | 1.57% | -2.52% | -32.42% | 50.42% | -21.32% | - |
Enterprise Value | 14,973 | 13,828 | 13,693 | 19,206 | 12,782 | 15,944 |
Last Close Price | 25.86 | 23.00 | 22.61 | 32.68 | 21.14 | 26.04 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
PE Ratio | 26.95 | 26.13 | 18.40 | 26.44 | 24.93 | 37.74 |
Forward PE | 23.72 | 16.50 | 13.27 | 25.05 | 21.53 | 33.48 |
PS Ratio | 1.82 | 1.65 | 1.57 | 2.28 | 1.67 | 2.26 |
PB Ratio | 4.69 | 4.52 | 4.89 | 6.04 | 5.49 | 7.32 |
P/TBV Ratio | 6.15 | 5.84 | 6.25 | 7.12 | 5.58 | 7.50 |
P/FCF Ratio | 39.04 | 19.22 | 24.96 | 30.67 | 62.46 | 103.45 |
P/OCF Ratio | 20.68 | 13.28 | 15.64 | 23.55 | 40.94 | 87.76 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
EV/Sales Ratio | 2.01 | 1.84 | 1.69 | 2.33 | 1.70 | 2.26 |
EV/EBITDA Ratio | 18.23 | 17.45 | 13.11 | 17.30 | 17.37 | 25.05 |
EV/EBIT Ratio | 20.86 | 19.12 | 13.95 | 18.25 | 17.94 | 25.94 |
EV/FCF Ratio | 43.01 | 21.42 | 26.86 | 31.28 | 63.77 | 103.66 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Debt / Equity Ratio | 1.32 | 1.23 | 0.92 | 0.47 | 0.59 | 0.56 |
Debt / EBITDA Ratio | 4.64 | 4.09 | 2.23 | 1.28 | 1.74 | 1.87 |
Debt / FCF Ratio | 10.95 | 5.24 | 4.68 | 2.37 | 6.67 | 7.97 |
Net Debt / Equity Ratio | 0.37 | 0.36 | 0.34 | 0.03 | 0.12 | -0.04 |
Net Debt / EBITDA Ratio | 1.36 | 1.23 | 0.84 | 0.07 | 0.36 | -0.14 |
Net Debt / FCF Ratio | 3.08 | 1.52 | 1.71 | 0.13 | 1.31 | -0.59 |
Asset Turnover | 0.94 | 0.99 | 1.20 | 1.44 | 1.56 | 1.64 |
Inventory Turnover | 4.85 | 5.20 | 5.84 | 7.28 | 8.52 | 8.55 |
Quick Ratio | 1.05 | 1.12 | 1.19 | 1.69 | 1.29 | 1.38 |
Current Ratio | 1.43 | 1.44 | 1.57 | 2.14 | 1.64 | 1.70 |
Return on Equity (ROE) | 22.01% | 21.39% | 26.80% | 28.55% | 21.80% | 22.60% |
Return on Assets (ROA) | 5.65% | 5.94% | 9.07% | 11.49% | 9.25% | 8.93% |
Return on Invested Capital (ROIC) | 14.91% | 15.90% | 23.33% | 27.47% | 22.37% | 23.81% |
Return on Capital Employed (ROCE) | 16.70% | 17.50% | 25.50% | 26.10% | 29.40% | 27.90% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 20, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Jan '22 Jan 1, 2022 |
Earnings Yield | 3.78% | 3.83% | 5.44% | 3.78% | 4.01% | 2.65% |
FCF Yield | 2.56% | 5.20% | 4.01% | 3.26% | 1.60% | 0.97% |
Dividend Yield | 2.13% | 2.48% | 3.37% | - | 3.60% | 2.56% |
Payout Ratio | 91.89% | 98.50% | 65.05% | 61.81% | 80.11% | 13.22% |
Buyback Yield / Dilution | 0.18% | 1.29% | -0.92% | -2.37% | -5.44% | -5.50% |
Total Shareholder Return | 2.31% | 3.77% | 2.45% | -2.37% | -1.83% | -2.94% |